血清可溶性白介素-2受体水平作为毛细胞白血病肿瘤负荷标志物及其预后价值和疾病监测工具
研究评估血清可溶性白介素-2受体(sIL-2R)在毛细胞白血病(HCL)中作为预后因素和疾病监测工具的作用。sIL-2R与肿瘤负荷标志物良好相关,治疗后显著下降,完全缓解者(p=0.002)或微小残留病(MRD)阴性者(p=0.034)水平更低。治疗后sIL-2R≤827 kU/L强烈预测更长的至下次治疗时间(TTNT)(中位未达到 vs 4.87年;HR 0.10;95%CI 0.02-0.24;p<0.001)。
要点
- sIL-2R与HCL肿瘤负荷标志物良好相关,治疗后显著下降。
- 完全缓解者(p=0.002)或MRD阴性者(p=0.034)治疗后sIL-2R水平更低。
- 治疗后sIL-2R≤827 kU/L与更长TTNT相关(HR 0.10;95%CI 0.02-0.24;p<0.001)。
核心结论
- sIL-2R有潜力作为非侵入性工具与MRD一起预测复发,并识别可能无法从当前治疗中获得最大益处的患者。
研究设计与样本
- 评估sIL-2R作为新预后因素和疾病监测工具作用的研究。
主要发现
- sIL-2R与其他肿瘤负荷标志物良好相关,治疗后显著下降,完全缓解者(p=0.002)或MRD阴性者(p=0.034)达到更低水平。
- 治疗后sIL-2R≤827 kU/L强烈预测更长TTNT(中位未达到 vs 4.87年;HR 0.10;95%CI 0.02-0.24;p<0.001)。
- 治疗后sIL-2R≤827 kU/L者5年和10年TTNT率更高(5年:93% vs 45%;10年:83% vs 11%)。
- 随访期间任意1年内sIL-2R水平升高≥50%预测即将复发。
关键数值与推荐
- 治疗后sIL-2R≤827 kU/L与更长TTNT相关(中位未达到 vs 4.87年;HR 0.10;95%CI 0.02-0.24;p<0.001)。
- 治疗后sIL-2R≤827 kU/L者5年TTNT率93% vs 45%,10年TTNT率83% vs 11%。
- 完全缓解者治疗后sIL-2R水平更低(p=0.002);MRD阴性者治疗后sIL-2R水平更低(p=0.034)。
- 随访期间任意1年内sIL-2R水平升高≥50%预测即将复发。
临床怎么用
- sIL-2R有潜力作为非侵入性工具与MRD一起用于预测复发和识别可能无法从当前治疗中获得最大益处的患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Leukaemic cells from hairy cell leukaemia (HCL) secrete a soluble form of the interleukin-2 receptor (sIL-2R) which is measurable in serum. Previous evidence suggested that sIL-2R may correlate well with tumour burden and demonstrated a reduction in sIL-2R levels after therapy with recombinant interferon-α2. We evaluated the role of sIL-2R as a new prognostic factor and as a tool for disease monitoring. sIL-2R correlated well with other markers of neoplastic bulk and markedly decreased after treatment, with lower levels achieved in patients reaching complete remission (p = 0.002) or negative minimal residual disease (MRD, p = 0.034). Post-treatment levels ≤827 kU/L were strongly predictive of longer time to next treatment (TTNT) (median NR vs. 4.87 years; hazard ratio [HR]: 0.10; 95% confidence interval [CI]: 0.02-0.24; p < 0.001) and higher 5- and 10-year TTNT rates (5-year: 93% vs. 45%; 10-year: 83% vs. 11%). Furthermore, a ≥50% increase in sIL-2R levels over any 1-year interval during follow-up predicted impending relapse. In a context where patients with HCL are expected to achieve a life expectancy comparable to that of the general population, sIL-2R has the potential to serve as a non-invasive tool alongside MRD to predict relapse and to identify those patients who may fail to derive the most benefit from current treatments.
引用
- Angotzi F, Cellini A, Danesin N, et al. Serum soluble interleukin-2 receptor levels in hairy cell leukaemia as a marker of tumour burden with prognostic value and as a tool for disease monitoring. Br J Haematol. 2025. PMID: 40734248. doi:10.1111/bjh.70059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。